Ocugen, Inc. (NASDAQ:OCGN – Free Report) – Research analysts at Noble Financial cut their Q3 2026 EPS estimates for Ocugen in a note issued to investors on Friday, August 7th. Noble Financial analyst R. Leboyer now forecasts that the company will post earnings per share of ($0.06) for the quarter, down from their previous forecast of ($0.05). The consensus estimate for Ocugen’s current full-year earnings is ($0.22) per share. Noble Financial also issued estimates for Ocugen’s Q4 2026 earnings at ($0.07) EPS and FY2026 earnings at ($0.26) EPS.
A number of other brokerages also recently commented on OCGN. Wall Street Zen downgraded Ocugen from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings cut Ocugen from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 23rd. Finally, Canaccord Genuity Group decreased their price target on Ocugen from $12.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, May 27th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Ocugen has an average rating of “Moderate Buy” and a consensus price target of $9.50.
Ocugen Stock Performance
NASDAQ OCGN opened at $1.31 on Tuesday. The stock has a 50-day simple moving average of $1.34 and a two-hundred day simple moving average of $1.56. The firm has a market capitalization of $444.23 million, a P/E ratio of -5.04 and a beta of 2.21. Ocugen has a fifty-two week low of $0.96 and a fifty-two week high of $2.73. The company has a debt-to-equity ratio of 4.17, a quick ratio of 0.80 and a current ratio of 0.80.
Ocugen (NASDAQ:OCGN – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The company had revenue of $1.49 million for the quarter, compared to the consensus estimate of $0.89 million.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the business. Hennion & Walsh Asset Management Inc. boosted its holdings in Ocugen by 121.7% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 2,830,397 shares of the company’s stock worth $4,331,000 after buying an additional 1,553,672 shares during the last quarter. UBS Group AG raised its holdings in shares of Ocugen by 373.2% during the fourth quarter. UBS Group AG now owns 4,849,353 shares of the company’s stock valued at $6,547,000 after acquiring an additional 3,824,474 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Ocugen during the fourth quarter valued at approximately $289,000. Cora Capital Advisors LLC lifted its position in shares of Ocugen by 27.5% in the fourth quarter. Cora Capital Advisors LLC now owns 30,143 shares of the company’s stock valued at $41,000 after acquiring an additional 6,500 shares in the last quarter. Finally, CTC Alternative Strategies Ltd. purchased a new position in shares of Ocugen in the first quarter valued at approximately $34,000. Hedge funds and other institutional investors own 10.27% of the company’s stock.
Insider Transactions at Ocugen
In other Ocugen news, CFO Treerita Essali Johnson-Greene acquired 21,000 shares of the company’s stock in a transaction on Monday, June 15th. The shares were bought at an average cost of $1.23 per share, with a total value of $25,830.00. Following the completion of the acquisition, the chief financial officer owned 521,000 shares in the company, valued at approximately $640,830. This trade represents a 4.20% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 3.95% of the company’s stock.
Ocugen News Roundup
Here are the key news stories impacting Ocugen this week:
- Negative Sentiment: HC Wainwright cut its estimates across several periods. The firm lowered its FY2026 EPS forecast to a loss of $0.28 from $0.25, FY2027 to a loss of $0.36 from $0.26, and FY2028 to a loss of $0.41 from a prior estimate of $0.05. Quarterly estimates for Q3 2026 through Q4 2027 were also reduced, pointing to a longer period of expected operating losses. Ocugen analyst estimate report
- Negative Sentiment: Long-term earnings expectations were sharply downgraded. HC Wainwright reduced its FY2029 EPS forecast to $0.14 from $0.61 and FY2030 to $1.08 from $1.56. Although the estimates still imply a potential return to profitability, the much lower projections weaken the longer-term earnings outlook.
- Negative Sentiment: Noble Financial also lowered its forecasts. Noble cut its FY2026 EPS estimate to a loss of $0.26 from $0.22 and reduced Q3 2026 EPS to a loss of $0.06 from $0.05 and Q4 2026 to a loss of $0.07 from $0.06. These revisions reinforce concerns about near-term cash consumption and execution.
- Neutral Sentiment: The broader earnings picture remains speculative. Ocugen is expected to remain unprofitable in the near term, while the available estimates project profitability beginning in FY2029. With OCGN trading near its 50-day average and well below its one-year high, investor focus is likely to remain on clinical progress, funding needs and the company’s ability to convert its pipeline into revenue.
Ocugen Company Profile
Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.
In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.
Featured Articles
- Five stocks we like better than Ocugen
- China’s Athleisure Boom Is Not Lifting Every Brand Equally
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.
